David Easthope Rejoins Celent

David Easthope, a former analyst at Celent, has rejoined the firm’s Securities and Investment’s group as research director based in the Francisco office.

Easthope's expertise lies in global financial exchanges and market structure, advanced trading technology, and North American retail brokerage, according to today’s news.

Before to rejoining Celent, Easthope was a director of strategy at Charles Schwab, where he applied his market expertise gathered at Celent at one of the leading US retail brokerage firms.

According to his Linkedin profile, Easthope was a research analyst with Celent from May 2005 to June of 2010, and then became research director of the firm in May of 2010 following its acquisition by Oliver Wyman. In June of 2010, Easthop left Celent for the position at Charles Schwab. Earlier in his career, Easthope held positions in capital markets including brokerage firm Detwiler Fenton as a business strategist. He also held sell-side equity research positions at Raymond James & Associates and at Friedman, Billings, Ramsey covering companies in the financial technology industry.

As part of an initiative to grow the Celent Securities & Investments team, Easthope's research will focus on themes of strategic importance in the capital markets and retail brokerage sectors, including the evolution of market structure, the development of advanced and algorithmic trading, and new platform and product innovations.

"The whole team is delighted to welcome David back to focus on our capital markets agenda," comments Mayiz Habbal, PhD, SVP of Celent's Securities & Investments group, in the release. "Celent is committed to expanding our Securities & Investments coverage, and David brings a wealth of experience and expertise to our growing practice."

Ivy is Editor-at-Large for Advanced Trading and Wall Street & Technology. Ivy is responsible for writing in-depth feature articles, daily blogs and news articles with a focus on automated trading in the capital markets. As an industry expert, Ivy has reported on a myriad ... View Full Bio